PDF(Pubmed)
Abstract：
Checkpoint inhibitors have been implicated in the treatment of several cancers due to their ability to exploit the immune system\'s regulatory pathways. This article serves to emphasize the importance of these immunotherapeutic agents and provide further insight into their mechanisms, efficacies, and safety profiles. The main agents in question include programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1). Several literature sources were found to assess the use of these inhibitors in cancers involving the lung, breast, and skin. Several peer-reviewed systematic reviews and the outcomes of clinical trials are combined within this article to support the use and further investigation of these agents in treating neoplasms. Further research into these forms of therapy underscores the revolutionary advancement of oncological interventions, which is important given the rising incidence of neoplasms within populations.
摘要：
检查点抑制剂由于能够利用免疫系统的调节途径而与几种癌症的治疗有关。本文旨在强调这些免疫治疗剂的重要性，并提供对其机制的进一步了解。功效,和安全概况。所讨论的主要试剂包括程序性细胞死亡蛋白1(PD-1)和程序性死亡配体1(PD-L1)。发现了一些文献来源来评估这些抑制剂在涉及肺癌的癌症中的用途。乳房,和皮肤。本文结合了一些同行评审的系统评价和临床试验的结果，以支持这些药物在治疗肿瘤中的使用和进一步研究。对这些治疗形式的进一步研究强调了肿瘤干预的革命性进步，考虑到人群中肿瘤发病率的上升，这一点很重要。
